- Takeda Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Amgen Inc.
- Cell Genesys Inc.
- Alnylam Pharmaceuticals Inc.
- Takeda Oncology
- Takeda California Inc.
- Takeda Pharmaceuticals USA Inc.
- TAP Pharmaceutical Products Inc.
- Abbott Laboratories Inc.
- Daiichi Sankyo Co. Ltd.
- Ranbaxy Laboratories Ltd.
- Astellas Pharma Inc.
- Eisai Co. Ltd.
- Regeneron Pharmaceuticals Inc.
- CoMentis Inc.
- Agensys Inc.
- Morphotek Inc.
- MGI Pharma Inc.
- Sucampo Group
- Merck KGaA
- AstraZeneca PLC
- Xoma Corp.
- Archemix Corp.
- Celgene Corp.
- MedImmune LLC
- Takeda Cambridge Ltd.
- Ambrx Inc.
- H. Lundbeck AS
- Myriad Genetics Inc.
- Takeda gets Japanese rights to 13 Amgen compounds
- Takeda to sell GVAX immunotherapy for Cell Genesys; ends
- Takeda signs RNAi deal with Alnylam
- Takeda to buy Millennium for $8.2bn in cash
- Abbott and Takeda end TAP joint venture after 30 years
- Daiichi to buy majority of Indian generics giant Ranbaxy
- Astellas develops antibodies using Regeneron's VelocImmune
- Astellas signs $760mm deal for beta-secretase inhibitors; CTS21166 program terminated; entire deal ended
- Astellas buys Agensys for $387mm plus earn-outs
- Pfizer to help develop and market Eisai's Alzheimer's drug
- Eisai to acquire US biotech Morphotek for $325mm
- Eisai buys MGI Pharma
- Eisai markets Pfizer's Cerebyx for seizures
- Eisai promotes Pfizer's Fragmin in the US
- Sucampo, Takeda enter constipation drug deal
- Merck KGAA and Takeda co-develop cancer treatment; ended
- Merck, Schering-Plough develop cholesterol, respiratory drugs
- Takeda acquires Syrrx
- Xoma and Takeda develop therapeutic antibodies
- Takeda develops aptamer compounds with Archemix
- AstraZeneca buys MedImmune for $15.6bn
- Takeda to buy Paradigm Therapeutics
- Takeda and H. Lundbeck in $385mm depression deal
- Lundbeck to sell Myriad's Flurizan in Europe;terminated
- Roche brings in RNAi capabilities through Alnylam deal' Arrowhead takes over deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.